The blood-brain barrier (BBB) is formed by brain capillary endothelial cells supported by astrocytes and pericytes. It serves as a highly selective, impermeable barrier that protects the brain's integrity and maintains homeostasis between the brain and the surrounding environment. The BBB selectively permits the transport of essential nutrients required for neuronal metabolism while actively removing potentially harmful substances from the brain. Only small, lipophilic molecules with a molecular weight below 400 Da can cross the BBB, whereas most large proteins and genes are excluded unless specific transport systems are utilized.
The blood-cerebrospinal fluid barrier separates cerebrospinal fluid (CSF) from systemic circulation, safeguarding it from exposure to toxins, pathogens, and many drugs. The BCSFB consists of arachnoid epithelial cells in the subarachnoid CSF region and choroidal epithelial cells near the CSF ventricular chambers. These components form a selective permeability barrier, ensuring the stability of the neural microenvironment.
In the field of drug development, researchers have long sought effective and safe methods for delivering therapeutic agents directly to the brain. Among these, the nasal-to-brain (N2B) drug delivery route has emerged as a promising non-invasive technique.
What is Nasal-to-Brain Drug Delivery?
N2B drug delivery is distinct from common inhalation therapies. It bypasses the BBB to deliver drugs directly to the brain via the nasal cavity. Therapeutic agents are administered to the upper nasal cavity, where they traverse the cribriform plate and reach the olfactory receptor neurons embedded in the nasal mucosa. The drugs then penetrate the cerebral cortex and striatum through these neurons.
Currently, clinical treatments for brain diseases primarily involve non-invasive or invasive methods. Non-invasive methods like oral administration are hindered by challenges such as the first-pass effect and the BBB. Invasive approaches, including intravenous injection, intrathecal injection, and intracerebral administration, can improve brain delivery efficiency but often pose risks of neurotoxicity, making them unsuitable for long-term treatment. N2B drug delivery presents a favorable alternative by bypassing the BBB to directly deliver drugs into the brain, minimizing systemic exposure, reducing toxicity, and enhancing therapeutic efficacy.
This non-invasive route avoids the first-pass effect, rapidly delivers drugs to the brain, and circumvents gastrointestinal degradation and enzymatic breakdown. It is characterized by fast absorption, painless application, and suitability for repeated use. The primary mechanisms for N2B delivery include the olfactory nerve pathway, the trigeminal nerve pathway, and systemic circulation. The olfactory pathway involves intracellular and paracellular transport via sensory neurons, while the trigeminal pathway facilitates drug transport from the nasal cavity to the brainstem and forebrain. Additionally, the highly vascularized respiratory region of the nasal cavity allows indirect drug absorption into systemic circulation.
Advantages and Challenges of Nasal-to-Brain Delivery
Advantages:
- Large Surface Area and Vascularization: The nasal mucosa offers a large, vascularized surface area for rapid drug absorption and onset of action.
- Avoidance of Gastrointestinal and First-Pass Metabolism: This pathway provides a direct route to the brain, avoiding harsh gastrointestinal conditions and hepatic metabolism.
- Non-Invasiveness: Compared to intravenous or intramuscular injections, N2B delivery is non-invasive, painless, and suitable for self-administration, improving patient compliance for chronic conditions.
Challenges: Despite its potential, N2B delivery faces several limitations:
- Mucociliary Clearance and Enzymatic Degradation: These natural defense mechanisms may reduce drug retention and efficacy.
- Toxicity Concerns: Long-term safety remains uncertain, particularly regarding mucosal and neuronal toxicity.
- Absorption Enhancers and Mucoadhesive Polymers: While these additives can improve drug delivery, their long-term effects on nasal tissues require further investigation.
Current Applications of Nasal-to-Brain Drug Delivery
The primary focus of N2B delivery research is on macromolecular drugs, such as peptides, proteins, and nucleic acids. While few biologics have reached the market, notable examples include:
- GnRH Analogues: Used for treating hormone-dependent metastatic prostate cancer.
- Desmopressin: Approved for nocturnal enuresis and central diabetes insipidus.
- Calcitonin: Indicated for osteoporosis treatment.
In psychiatric applications, loxapine received FDA approval in 2012 for controlling agitation in schizophrenia and bipolar disorder patients. Meanwhile, intranasal insulin and its analogues are undergoing clinical trials, offering hope for chronic disease management.
Emerging Strategies to Enhance Nasal-to-Brain Delivery
To overcome the restrictive properties of the BBB, researchers are exploring various nanocarrier systems and drug delivery platforms, including:
- Permeation Enhancers and Enzyme Inhibitors: These strategies improve drug bioavailability across the nasal mucosa.
- Prodrugs and Mucoadhesive Polymers: Designed to enhance retention and stability within the nasal cavity.
Nanotechnology-based approaches, such as nanoparticles (NPs), offer a compelling alternative. NPs include liposomes, nanoemulsions, lipid-based NPs, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), polymeric NPs, and metal-based NPs. Following intranasal administration, these NPs traverse the olfactory and trigeminal nerve pathways, delivering therapeutic agents to targeted brain regions. This method holds significant promise for treating central nervous system injuries and neurodegenerative disorders.
Nasal-to-brain (N2B) drug delivery offers a groundbreaking approach to bypassing the BBB and directly targeting the brain. While the method presents unique advantages, including non-invasiveness and rapid brain access, challenges such as mucosal toxicity and delivery efficiency must be addressed. Advances in nanotechnology and innovative carrier systems are expected to drive future developments, expanding the therapeutic possibilities for central nervous system disorders.
Prisys Biotech, as a leading preclinical large-animal CRO, possesses the capability to conduct N2B experiments in non-human primates such as Cynomolgus Macaque. Additionally, Prisys Biotech offers advanced CNS research services and technologies. For more information, please feel free to contact us.
